Return to homepagePandemic Pact

COVID-19 and RAS Inhibition

Grant number: unknown

Grant search

Key facts

  • Disease

    COVID-19

  • Start & end year

    2020
    2021

  • Known Financial Commitments (USD)

    $457,860.06

  • Funder

    FWF

  • Principal Investigator

    Manfred Hecking

  • Research Location

    Austria

  • Lead Research Institution

    Medizinische Universität Wien - Universitätsklinik für Innere Medizin III

  • Research Priority Alignment

    N/A

  • Research Category

    Clinical characterisation and management

  • Research Subcategory

    Clinical trials for disease management

  • Special Interest Tags

    N/A

  • Study Type

    Clinical

  • Clinical Trial Details

    Randomized Controlled Trial

  • Broad Policy Alignment

    Pending

  • Age Group

    Unspecified

  • Vulnerable Population

    Unspecified

  • Occupations of Interest

    Unspecified

Abstract

https://innere-med-3.meduniwien.ac.at/nephrologie/wissenschaft-forschung/hd-co-research-group/ COVID-19, SARS Virus, Angiotensin Converting Enzyme 2, Renin Angiotensin System, Angiotensin-Converting Enzyme Inhibitors, Randomized Controlled Trial [From linked website: COVID-19 und RAS Blockade: Randomisiert, kontrollierte klinische Studie zu Wirksamkeit und Sicherheit von ACE-Hemmern und Angiotensin-II-Rezeptor-Blockern bei SARS-CoV-2 Infektion (Die COVID-19-RAS-Studie = Substudie B des Austrian CoronaVirus Adaptive Clinical Trial [ACOVACT])]